Loss of major histocompatibility class II (MHC II) expression in diffuse large B cell lymphoma (DLBCL) correlates with worse outcome, possibly from decreased immunosurveillance. Primary mediastinal B cell lymphoma (PMBCL) is a subtype of DLBCL which reportedly has frequent loss of MHC II proteins; however, PMBCL has better survival than DLBCL. To investigate this paradox, we used gene expression profiling (GEP) data and immunohistochemistry to study expression of MHC II and its regulatory genes and determine their relationship to PMBCL survival. We found that GEP levels correlated between MHC II genes and the transcriptional regulator MHC2TA but not other adjacent genes, implying transcriptional regulation of MHC II in PMBCL was intact and that MHC II gene deletion was unlikely. MHC II average expression was lower than in certain subtypes of DLBCL however, only 12% had complete loss of MHC II expression. Poor patient survival in PMBCL correlated with incremental decreases in MHC II expression. Although overall survival was better, survival of the lowest 10% of MHC II expressers was similarly poor in DLBCL and PMBCL. MHC II expression may define a therapeutic target in both these diseases.
ABSTRACT
Loss of major histocompatibility class II (MHC II) expression in diffuse large B cell lymphoma (DLBCL) correlates with worse outcome, possibly from decreased immunosurveillance. Primary mediastinal B cell lymphoma (PMBCL) is a subtype of DLBCL which reportedly has frequent loss of MHC II proteins; however, PMBCL has better survival than DLBCL. To investigate this paradox, we used gene expression profiling (GEP) data and immunohistochemistry to study expression of MHC II and its regulatory genes and determine their relationship to PMBCL survival. We found that GEP levels correlated between MHC II genes and the transcriptional regulator MHC2TA but not other adjacent genes, implying transcriptional regulation of MHC II in PMBCL was intact and that MHC II gene deletion was unlikely. MHC II average expression was lower than in certain subtypes of DLBCL however, only 12% had complete loss of MHC II expression. Poor patient survival in PMBCL correlated with incremental decreases in MHC II expression. Although overall survival was better, survival of the lowest 10% of MHC II expressers was similarly poor in DLBCL and PMBCL. MHC II expression may define a therapeutic target in both these diseases.
INTRODUCTION
Primary mediastinal large B cell lymphoma (PMBCL) is considered to be a subset of diffuse large B cell lymphoma (DLBCL), characterized by predominant mediastinal involvement, of large B cells with clear cytoplasm, convoluted or centroblastic nuclei, and thin bands of compartmentalizing sclerosis. 1 Immunophenotypically, PMBCL is unusual among mature B cell neoplasms in that, despite expression of B cell surface antigens including CD20 and CD79a, and IgH rearrangements and mutations, PMBCL cells usually lack surface IgG and according to the World Health Organization's classification, loss of expression of the major histocompatibility class II proteins (MHC II).
1,2 Unlike DLBCLs, PMBCLs frequently over express MAL, an integral membrane protein usually found in lipid rafts, which is also expressed in certain normal thymic medullary B cells, from which PMBCLs may be derived. 3 Cases of PMBCL also tend to exhibit genetic abnormalities involving chromosomal gains at 9p, associated with increased expression of JAK2 at 9p24, and 2p, associated with the REL locus at 2p16. 4, 5 Unlike DLBCLs, PMBCLs seldom exhibit BCL2 or BCL6 rearrangements or translocations. 6 PMBCL patients are typically younger than patients with other subtypes of DLBCL and may show female predominance. The disease is aggressive, and can involve multiple thoracic structures (lung, pericardium, breast) but is less likely than other DLBCLs to extend to extrathoracic regions. 7 As a subset of DLBCL, PMBCL is currently treated similarly, with adriamycin-containing combination chemotherapy regimens, and monoclonal antibody therapy. Involved-field radiation therapy is often added to debulk localized disease. 8 Survival and responses to treatment of PMBCL have been controversial, possibly because of confusion of this disease with other subtypes of DLBCL arising in the mediastinal area. Some studies have reported substantially better outcome for PMBCL (82% at 3 years) 9 , and some have reported survivals that are very similar to or worse than other forms of DLBCL (approximately 50% at 5 years) 10 . Two recent studies, one at Dana Farber Cancer Institute 11 , and one at the NCI by the Leukemia and Lymphoma Molecular Profiling Project (LLMPP) 7 , have reported results of microarray gene expression profiling showing PMBCL to be a unique entity, separable from other subgroups of DLBCL. While in many ways resembling the germinal center-like subtype of DLBCL, PMBCL also had increased expression of a number of genes characteristically expressed in Hodgkin lymphoma (HL). The Dana Farber study also noted lower expression of specific MHC II genes in PMBCL, in agreement with previous immunohistochemical studies. 11 MHC II genes are a family of genes, mostly expressed from a single locus on chromosome 6p. 12 These genes are constitutively expressed in antigen-presenting cells, such as B cells, dendritic cells, monocytes, and macrophages, with inducible expression in many other cell types. The proteins deriving from these genes present peptide antigens derived from exogenous proteins to CD4+ T cells. MHC II proteins are divided into 2 types, classical and non-classical. Classical proteins consist of HLA-DR, -DP, and -DQ, each of which are heterodimers of an alpha and beta protein, encoded by A and B genes. 13 Classical proteins are directly responsible for displaying peptide antigens on the cell surface. Non-classical proteins assist in and modulate the function of the classical proteins, and consist of HLA-DM, -DO, and invariant chain (Ii, CD74). HLA-DM and -DO are also heterodimers similar to the classical proteins. Invariant chain, unlike the other MHC II proteins, is expressed from a gene on chromosome 5q.
A recent large study of DLBCL by the LLMPP has determined that specific MHC II genes constitute one of four prognosis-related gene signatures. 14 The MHC class genes all have similar sites in their regulatory regions for the cooperative binding of a transcriptosome complex of RFX, NF-Y and CREB. This complex in turn creates a protein binding site for CIITA, which does not bind DNA directly. 13 CIITA (encoded by the MHC2TA gene) serves as a master transactivator of the MHC II genes. CIITA expression is usually highly correlated with MHC II expression in most normal cell types where it is expressed. Loss of functional expression of any of the 3 genes encoding the subunits of the heterotrimer RFX or of the MHC2TA gene encoding CIITA leads to elimination of all MHC II expression, as evidenced in the congenital immunodeficiency diseases known as the MHC II deficiency syndromes. 15 Loss of expression of MHC II genes is reportedly a common event in DLBCL involving immuneprivileged sites like testes, ovary, eye, or brain. 16 Immune-privileged DLBCL (IP-DLBCL) is relatively rare and different clinically and phenotypically from other DLBCLs, and occurs most commonly in patients who are immunodeficient. It has been reported that IP-DLBCL of brain or testis shows loss of expression of MHC II genes in over half the cases, and that this loss of expression is often accompanied by large homozygous or heterozygous deletions of the MHC II locus. 16, 17 In the same reports it was found that non-IP-DLBCL lost MHC II expression in 5% of cases without accompanying deletions of the 6p locus. In agreement with these findings, we have recently reported that complete loss of MHC II expression occurs in only about 10% of DLCBL in a dataset of 240 de novo DLBCL, and found evidence for MHC II locus deletions in less than 1%, although all patients with MHC II expression below the median had a poorer outcome. 18, 19 Since the mechanism for loss of MHC II expression in DLBCL does not usually appear to involve loss of the genes themselves, but probably genetic or epigenetic regulation, it may be possible to restore the expression of these genes.
Another possible mechanism of loss of MHC II expression may be specific to PMBCL. Loss of functional expression of the signaling molecule SOCS1, a gene located on chromosome 16p13, in the near vicinity of MHC2TA, was shown in 9 of 20 primary PMBCL samples and 2 of 2 PMBCL cell lines. 20, 21 Although these losses of SOCS function were shown in all but 1 case to be due to small insertions or deletions within the SOCS gene, one PMBCL cell line, Karpas 1106, had a biallelic deletion of ~700 Kb, in the region including SOCS1. 21 Although this specific deletion did not include MHC2TA, deletions of this size involving SOCS1 certainly could, since the MHC2TA gene is within 400 Kb of SOCS1.
The purpose of the present work was to study the patterns of expression of MHC II and regulatory genes in PMBCL, relate these patterns to protein expression and possible deregulation with neoplasia, and determine how these patterns are related to patient survival.
PATIENTS, MATERIALS, AND METHODS

PMBCL and DLBCL clinical, gene expression profiling, and comparative genomic hybridization data
In 2003, the Leukemia and Lymphoma Molecular Profiling Project (LLMPP) published a report on the development of a molecular PMBCL predictor for distinguishing PMBCL from other types of DLBCL. 7 This paper used a training set of 35 cases and a validation set of 274 cases of DLBCL, for which gene expression data from the Lymphochip microarray were available. Lymphochip type II microarray data consist of relative gene expression derived from the ratio of fluorescence of sample mRNA to a reference mRNA made from multiple pooled cell lines. The Lymphochip probes consist of more than 12,000 cDNA expressed sequence tags (ESTs) derived from a number of libraries enriched for genes related to lymphoid cells or believed to play a role in cancer or immune function. 22 We used a subset of this data consisting of de novo untreated cases only, for which clinical information was available. Forty-two cases were classified as PMBCL by the molecular predictor (23 from the training set and 19 from the validation set) and 221 cases were classified as other types of DLBCL. Thirty of the 42 cases classified as PMBCL were originally clinically considered to be PMBCL, with mediastinal presentation, and the rest were originally considered DLBCL, but were classified as PMBCL by gene expression predictor score. These included 82 cases of activated B cell-like (ABC) DLBCL, 95 cases of germinal center B cell-like (GCB) DLBCL, and 44 cases of DLBCL that could not be identified with either group (Unclassified). In addition, there were 9 samples of different types of normal B cells. For the purposes of this paper, our definition of PMBCL is that of the molecular predictor.
The cases from the training and validation sets in the LLMPP PMBCL paper 7 had been compared to different reference pools. Therefore, it was first necessary to adjust for the differences between the reference pools. The two sets originally consisted of log2 transformed fluorescence ratios between each sample and reference, representing different ESTs, normalized so that the median of the well measured spots was set to 0. To normalize the test set to the validation set, 25 DLBCLs from the validation set were re-arrayed using the new reference. For each gene, we considered the pairwise difference between the log2 ratios of these samples with the old and new references. We then subtracted the median of these differences from all of the log2 ratios of that gene on all of the training set data.
ESTs representing the MHC II family genes, MHC2TA, RFX, and genes located near or within the MHC II locus on chromosome 6p21 and the MHC2TA location on chromosome 16p13 were sought in the microarray database. Table 1 is a list of these genes and their location relative to the MHC II genes or to MHC2TA. Expression data for all the subunits of RFX and HLA-DO were not found, so these genes were excluded from further analysis. Multiple ESTs representing many of the genes were found in the data. In the case of multiple representations of a single gene, all of the ESTs for that gene were averaged to a single gene expression value. Overall, average MHC II expression was defined as the average of the expressions of HLA-DRA, -DRB, -DPA, -DPB, -DQA, -DQB, -DMA, -DMB, and CD74. Data for Figure 3 was mediancentered.
Chromosome comparative genomic hybridization (CGH) data from 16 of the cases 23 were downloaded from http://www.ncbi.nlm.gov/projects/sky/.
Tissue Immunohistochemistry
Tissue sections or tissue microarray cores from paraffin-embedded tissues were available from 17 PMBCL samples from our dataset, for our use in validating the gene expression results. Approval was obtained from the University of Arizona institutional review board for these studies. Informed consent was provided according to the Declaration of Helsinki. Because the material was limited, we chose to use a single, representative MHC II molecule for staining. HLA-DR was chosen because it has been specifically related to survival in previous publications 24 , because it is by far the most highly expressed of the MHC II family, and because it has a readily available antibody (immunoglobulin G2b[IgG2b], Novocastra, Newcastle upon Tyne, United Kingdom). The antibody, at a 1:50 dilution, was optimized by epitoperecovery methods on an automated immunostainer (Ventana Benchmark System, Ventana Medical Systems, Tucson, AZ) with a biotin-avidin-diaminobenzidine-based detection system. Samples were counterstained with hematoxylin.
Immunohistochemistry results were initially examined by 2 hematopathologists (L.M.R. and M.A.J.) and a consensus counting methodology agreed on after an initial training session using a multiheaded microscope. Samples were then counted by one of the 2 pathologists above. As in our previous studies, an area of minimum intensity staining within the tumor was chosen, with the rationale that areas of tumor which have lost MHC II expression can escape immunosurveillance and are likely to contribute to poor prognosis. 19, 25 Approximately 200 tumor cells were counted per case, and each cell scored as negative or positive. The numbers of cells scored as positive were divided by total cells counted and multiplied by 100 for a percent positive score. Pathologists performing cell counts were blinded to the GEP results for the samples.
Data analysis
Overall survival was estimated by the method of Kaplan and Meier. Tests of differences in survival between groups were by the log-rank test. These were done on Statview software (version 4.5, Abacus Concepts, Inc.). Pearson correlations, t-tests for determining significance of differences in gene expression, and other statistical and mathematical manipulations of the data were done with Excel software (Microsoft Office version 10).
RESULTS
Coordination of MHC II gene and protein expression
First, we plotted the relative gene expressions of the individual MHC II genes and MHC2TA (Figure 1) . By visual inspection, the expression of the genes was coordinated between the MHC II genes and MHC2TA for cases with both high and low relative expression. In this study 5 of 42 (12%) PMBCL cases have substantial, coordinate loss of expression of all of the MHC II genes, which is similar to what we previously reported in DLBCL. 19 In all these cases of loss, except possibly case 691, coordination of MHC2TA expression with the other genes implies that transcriptional regulation may still be functioning even in low expressing cases.
To show that the microarray results were related to cellular display of the proteins, IHC was performed on the subset of PMBCL samples available to us (Figure 2A Then, to demonstrate the specificity of coordination of the expression of the MHC II genes and their transcriptional activator MHC2TA, we calculated Pearson correlation coefficients between the MHC II genes and their neighbors on chromosome 6p, CD74/Ii on chromosome 5, and MHC2TA on chromosome 16 ( Table 2 ). In the table, highly correlated expression is shown in dark gray, and this color is seen at the intersections of the MHC II genes with each other and with MHC2TA. This analysis demonstrated high correlation coefficients for the classical and non-classical MHC II genes within the class II locus (range: 0.76-DPA vs. DQB or DQA to 0.91-DRA vs. DRB or DPB) and between CD74 and MHC II genes (range: 0.71 vs. DQA to 0.88 vs. DRA). However, correlations between MHC II genes (including CD74) and genes adjacent to or within the MHC II locus were lower and did not overlap (range: -0.12-DMA vs. RING1 to 0.25-DRB vs. DAXX). In addition, correlation between the transactivator gene MHC2TA and any of the MHC II genes including CD74 was higher (range: 0.54 vs. DPA to 0.63 vs. DQB or CD74) than between MHC2TA and the genes adjacent to or within the MHC II locus (range: -0.12 vs. BAT8 to 0.26 vs. DAXX). These results implied that there was no larger global regulation of the MHC II gene locus, (for example extended locus methylation) but that the MHC II genes are specifically regulated in our PMBCL data set.
Possibility of large deletions of DNA as explanation of MHC II loss
Since large genetic deletions in the MHC II locus have been implicated in the loss of MHC II expression in IP-DLBCL, we made a positional expression profile 26 of the expression of genes located near or within about 500 Kb of the MHC II locus, for which we had GEP data ( Figure 3A ). Relative locations of these genes are listed in Table 1 . Our rationale was that if genes located near or between the MHC II genes which have been down-regulated were still being expressed at levels similar to or higher than those in normal cells in the individual cases, large deletions probably did not exist within the locus in those cases. 18 The data show that in the 5 cases with lowest MHC II expression as well as in the other cases, that the expression of genes between and around the MHC II genes was not decreased, implying that the MHC II genes are not down-regulated by large deletions in our PMBCL cases.
Another way that the MHC II genes could be coordinately down-regulated would be by deletion of the MHC2TA gene, which is the master transactivator for all MHC II expression. A recent report of a homozygous deletion found in the vicinity of the MHC2TA gene at the SOCS1 locus 21 prompted us to make a positional expression profile for the genes near the MHC2TA locus as well. Genes on chromosome 16p13 near MHC2TA were much sparser in the microarray data than genes in the MHC II locus, but those found were mapped in Figure 3B . Of the lowest expressing cases of PMBCL, shown at the top of the map, only cases 1006 and 1993 show substantial down-regulation of both SOCS1 and MHC2TA indicating the possibility of a large deletion including MHC2TA. It is difficult to extrapolate the possibility of an MHC2TA deletion from the low expression of the SOCS1 gene, as it is expressed at very low levels in most of the normal B cells as well as in the PMBCL cases. However, most of the samples do not show coordinate down-regulation of MHC2TA and adjacent genes, minimizing the possibility of large deletions in the MHC2TA locus in most of the PMBCL cases.
Sixteen of the PMBCL cases (Figure 3 ) had published CGH data available, and no large deletions in either the MHC II at 6p or the MHC2TA locus at 16q were found by this technique, including for case 1006.
Expression of MHC II genes in DLBCL subtypes
Because it has been reported that PMBCL shows frequent loss of MHC II expression compared to other types of DLBCL 11 , we analyzed the average relative expression of MHC II genes in PMBCL compared to the average relative expression of these genes in other types of DLBCL (Figure 4) . PMBCL had significantly lower expression of all of the individual MHC II genes except CD74, and lower expression of the MHC II average, than the GCB subtype, which is the most common subtype of DLBCL. Expression of most of the MHC II genes was not significantly different in PMBCL than in the ABC subtype and Unclassified DLBCL cases. Only HLA-DMA expression in PMBCL was significantly lower in all the subtypes. The average MHC II gene expression of the normal cells was extremely variable (see 3A, bottom), and there were few or no replicates of the normal cell types, so it was not possible to say with confidence how the expression of the MHC II genes in any of the DLBCL subtypes compared to normal cells. Figure 5 shows Kaplan-Meier plots of cumulative survival vs. MHC II average gene expression. The left side shows the low 10% of MHC II gene expressers vs. the rest of the cases. This division was used in order to be able to compare the low 10% of PMBCL cases with our previous data from the low 10% of other DLBCLs 27 . The right side shows 4 approximately equal groups of increasing gene expression, to show that survival increases significantly and incrementally with increasing gene expression. The 5 year survival estimates for plot A on the left were 68% for those patients in the >10% to 100% expression level vs. 25% for patients in the lowest 10% expression levels. The 5 year estimates for survival for plot B on the right were 91% in the >75% to 100% group, 69% in the >50% to 75% group, 58% in the >25% to 50% group, and 34%for those patients in the lowest 25% of expression.
MHC II gene expression and survival and clinical features
Since there was insufficient clinical data collected for the majority of the samples to calculate the International Prognostic Index (IPI), it was not possible to compare the prognostic value of the MHC II genes to the IPI to determine whether MHC II expression was an independent survival predictor. The IPI is composed of 5 risk factors which each can be given a score of 0 or 1, the lower values corresponding to 0 in all cases; the risk factor scores are summed to equal the IPI. 28 The risk factors are stage (1 or 2 vs. 3 or 4); age (≤ 60 vs. > 60); LDH (lactate dehydrogenase) levels (≤ normal vs. > normal); performance status (0 or 1 vs. ≥ 2); and number of extranodal sites (≤ 1 vs. >1). Information was available for all of the risk factors except the number of extranodal sites. We therefore calculated the values for all of the individual risk factors possible and found that these were not individually significantly predictive of survival (data not shown). Then we calculated a partial IPI score, consisting of the sum of the 4 risk factor scores for which we had clinical information, and this was not significantly predictive of survival either (data not shown), whether divided into halves (0 or 1 vs. 2 or 3) or into the 4 individual numbers.
We found no clinical differences between the lower and higher MHC II expressers except survival, using the limited clinical data. There were no significant differences with decreasing MHC II expression in location (North America vs. Europe), performance status, LDH level, gender, or stage. Among the 4 patients in the lowest 10% of MHC II expression, there were 2 females and 2 males. Two were diagnosed in the 3 rd decade of life, one in the 4 th , and one in the 6 th . One patient was in stage II, one in stage III, two in stage IV. The serum LDH level was above the upper limit of normal 2 patients and within normal limits in the other 2 patients. Two patients each were from the United States and Europe.
DISCUSSION
In this study, we have demonstrated that loss of MHC II molecules is not characteristic of PMBCL, and is similar to non-GCB subtypes of DLBCL. However, when loss of expression does occur, those cases have the same extremely poor clinical outcome as MHC II negative DLBCL. Using positional expression profiling and CGH, we did not find evidence of large deletions at the MHC II or CIITA loci, implying that the genes are intact and may be targets for therapeutic manipulation.
Similar to what we previously reported in DLBCL, about 10% of the cases of PMBCL appeared to have substantial loss of expression of all the MHC II genes by GEP. 27 This was in contrast to previous IHC studies which had shown loss of MHC II expression in PBMCL on a much larger percentage of cases, sometimes in a majority of those studied, 9,29 but similar to a recent study showing only 20% of samples losing HLA-DR staining. 30 Previous studies of HLA-DR expression on different sets of archival non-PMBCL DLBCL samples which had undergone different preservation and storage conditions, reported about 5% and 40% do not stain for this MHC II protein. 16, 27, 31 In fact, the WHO classification of lymphoid neoplasms describes the characteristic immunophenotype of PMBCL as negative for MHC II. 1 Our speculation is that GEP was a more sensitive indicator of the presence of lowered levels of MHC II expression than IHC, which appears to have a variable threshold for detection of HLA-DR and tends to overestimate the number of non-MHC II-expressing cases.
The average expression of the MHC II genes in PMBCL cases appeared to be slightly lower than that in the most common subtype of DLBCL, the GCB subtype, and similar to the average expressions of the genes in the ABC subtype, and in the Unclassified cases, from the LLMPP data. This was unexpected because the PMBCL subtype most closely resembles the GCB subtype in other GEP respects. In fact, the 19 PMBCL cases from the validation set were all classified as GCB by the original DLBCL predictor, prior to the development of the molecular predictor for PMBCL. Since the differences between average expression of the MHC II genes may be due to differences in MHC II gene expression in the B cell subsets from which the tumors were derived, it would be interesting to compare the DLBCL data to normal B cell expression data. However, our dataset was limited by the fact that it had so few and such variable and highly processed samples of normal B cell populations to compare our tumor samples with. MHC II gene expression varies during differentiation of the B cell lineage. MHC II genes are not expressed in pro-B cell populations, are highly expressed by mature B cells, and their expression is extinguished by down-regulation of expression of CIITA protein during maturation into plasma cells. 32 GCB DLBCL cell lines have a different reaction to IL-4 signaling than ABC DLBCL. In GCB DLBCL cell lines, IL-4 induces expression of its known STATinduced target genes, while in ABC DLBCL lines it does not. 33 Since MHC II genes are IL-4 target genes in B cells, 13 if this difference also occurs in vivo it could explain the higher expression of MHC II genes in GCB DLBCL cases. It is also possible that the differences in expression between the different DLBCL subtypes are due to a different local environment, although this is unlikely since 5 GCB and 3 ABC samples of DLBCL from mediastinal locations were not significantly different in MHC II expression compared to GCB or ABC DLBCL samples from other sites (data not shown).
Interestingly, HLA-DM appeared to be expressed at a somewhat lower level in the PMBCL subtype than in the other DLBCL subtypes. HLA-DM is involved with modulation of the antigen-loading of the classical MHC II proteins, especially the replacement of CLIP (the degradation product of invariant chain which serves to block loading of endogenous antigens on the MHC II classical molecules ). 13 It would therefore be interesting to know whether the antigens displayed on classical MHC II molecules on the surface of PMBCLs are different from those on other DLBCLs, for instance if they are more frequently endogenous rather than exogenous antigens.
PMBCL also seemed to resemble other DLBCL subtypes in the relationship of loss of MHC II expression to survival. There were survival increases with increasing expression of MHC II genes across both DLBCL and PMBCL cases. Although the average expression of MHC II genes was lower in PMBCL than in some other types of DLBCL, and the overall survival generally higher, the estimated survival at 5 years of the lowest 10% MHC II expressers was very similar in both the DLBCL set (24%), from our previous work 27 , and the PMBCL (25%) subset in this publication. As a caveat, there were 3 samples from our validation set that were present in both the PMBCL lowest 10% expressers subset (n=4) and the DLBCL 10% lowest expressers subset (n=24). This does show, however, that the extent of substantial loss was similar in all the subtypes of DLBCL in our datasets.
The mechanism of lowered MHC II expression in PMBCL remains unclear. Our positional expression profiling analysis demonstrated PMBCL was unlikely to down regulate the expression of the MHC II genes by large genetic deletions in the MHC II locus, as had been previously described in IP-DLBCL. 16 PMBCL also did not appear in most cases of MHC II loss to have genetic deletions of the MHC2TA gene, which encodes CIITA, the major transactivator of the MHC II family, even though deletion of the SOCS1 gene, which is located near the MHC2TA gene, had been seen in a PMBCL cell line. 21 In summary, our data seemed to show that there could be similar mechanisms of substantial and partial loss of MHC II gene expression across the PMBCL, ABC, GCB, and Unclassified subtypes of DLBCL. Further investigations may extend our study of MHC II expression to other types of non-Hodgkin lymphoma (NHL), such as follicular, Burkitts, and mantle cell lymphoma, with the hypothesis that other types of NHL also have a range of MHC II expression related to survival, with a small subset showing substantial loss with extremely poor outcome. We are also investigating the mechanisms of down-regulation of the MHC II genes, including transcriptional or epigenetic regulation, as well as testing in vitro treatments for increasing MHC II expression in DLBCL. Our long-term goal is to therapeutically modify MHC II expression in patient tumors in the hope of improving patient outcome.
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